Science
Mechanism of Action
Mafenide HCL functions as a short-acting topical antibacterial by competitively inhibiting para-aminobenzoic acid (PABA), thereby disrupting bacterial folic acid synthesis essential for growth. This mechanism is effective against a range of bacteria, including *Pseudomonas aeruginosa*, and its activity remains unhindered by biological factors such as pus or serum. Mafenide and its primary metabolite also exhibit carbonic anhydrase inhibitory activity.
Research
Clinical Evidence
Medium confidence5%
Key findings
- 01 A 5% topical solution (Mafenide Acetate), applied under moist dressings, effectively controlled bacterial infection on excised burn wounds involving meshed autografts.
- 02 An 11.2% concentration in cream formulations for severe burns was associated with two to three times greater pain compared to 5% concentrations, with hypertonicity identified as the likely cause.
- 03 A 2.5% solution, when applied topically in a *Pseudomonas aeruginosa*-contaminated full-thickness skin graft model in rats, initially improved graft survival by day 7, but subsequently led to significant cytotoxicity and graft loss by day 14.
Transparency
Dusting Analysis
Mafenide HCL is a prescription-only medication approved for severe burn treatment, making its casual inclusion or 'dusting' in over-the-counter cosmetic formulations highly improbable and medically inappropriate due to its potency and significant safety considerations.
The Formula
Formulation
Stability
Mafenide Acetate is freely soluble in water. A reconstituted 5% topical solution can maintain stability for up to 28 days when stored in unopened containers at 20-25°C. However, once a container is opened, any unused portion should be discarded after 48 hours. *In vitro* studies suggest antimicrobial activity of 5% mafenide acetate can persist for at least 60 days post-reconstitution.
Conflicts
- Hypersensitivity to mafenide or any component of its formulation.
- Individuals with sulfonamide allergy (requires extreme caution).
- Other carbonic anhydrase inhibitors (e.g., dichlorphenamide), due to an increased risk of metabolic acidosis.
- Allogeneic cultured keratinocytes and fibroblasts, as mafenide can reduce their viability and disrupt structural integrity.
- Methenamine, articaine, insulin aspart, lidocaine, methotrexate (use generally not recommended or requires dose adjustment).
- Aminolevulinic Acid (may increase risk of certain side effects).
Safety
Safety Profile
Mafenide HCL was FDA-approved in 1948 and is exclusively a prescription-only medication. It is contraindicated in patients with known hypersensitivity to mafenide or any formulation component, and extreme caution is advised for individuals with sulfonamide allergy. It is classified as Pregnancy Category C. Potential adverse reactions include localized pain or burning sensations, rash, pruritus, erythema, facial edema, and skin maceration. Serious systemic side effects can include metabolic acidosis, particularly in patients with extensive burns or pre-existing pulmonary/renal dysfunction, due to its carbonic anhydrase inhibition. Fatal hemolytic anemia with disseminated intravascular coagulation has been reported, especially in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Prolonged use may foster fungal or bacterial superinfection. Mafenide has also been observed to reduce keratinocyte viability and disrupt the integrity of tissue-engineered human skin substitutes. PubChem notes a potential for allergic skin reactions.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Due to its status as a potent, prescription-only medication for severe burns, its high potential for irritation and cellular toxicity, and significant systemic adverse effects, Mafenide HCL is considered inappropriate and potentially harmful for cosmetic applications.
Related
Similar Ingredients
Finding similar ingredients…